{"id":474396,"date":"2020-03-17T10:34:01","date_gmt":"2020-03-17T10:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474396"},"modified":"2020-03-17T10:34:01","modified_gmt":"2020-03-17T10:34:01","slug":"benign-prostatic-hyperplasia-bph-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/benign-prostatic-hyperplasia-bph-market-insights-epidemiology-and-market-forecast2030_474396.html","title":{"rendered":"Benign prostatic hyperplasia (BPH) &#8211; Market Insights, Epidemiology, and Market Forecast-2030"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1584428517.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology, and Market Forecast-2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1584428517.jpeg\" alt=\"Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology, and Market Forecast-2030\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Benign prostatic hyperplasia (BPH) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Benign prostatic hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign prostatic hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Albany, NY &#8211;<\/strong> DelveInsight launched its new report on&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/benign-prostatic-hyperplasia-bph-market\" target=\"_blank\">Benign Prostatic Hyperplasia (BPH) Market Insights, Epidemiology and Market Forecast- 2030<\/a><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/benign-prostatic-hyperplasia-bph-market\" target=\"_blank\">Benign prostatic hyperplasia (BPH) &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/a>&#8221;&nbsp;report delivers an in-depth understanding of the Benign prostatic hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign prostatic hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Some key facts of the report:<\/strong><br \/><span>Benign Prostatic Hyperplasia (BPH) refers to the proliferation of epithelial and smooth muscle cells within the transition zone of the prostate.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<\/strong><br \/>1. The report covers the descriptive overview of Benign prostatic hyperplasia (BPH), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<br \/>2. Comprehensive insight has been provided into the Benign prostatic hyperplasia (BPH) epidemiology and treatment in the 7MM<br \/>3. Additionally, an all-inclusive account of both the current and emerging therapies for Benign prostatic hyperplasia (BPH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<br \/>4. A detailed review of Benign prostatic hyperplasia (BPH) market; historical and forecasted is included in the report, covering drug outreach in the 7MM.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages<\/strong>:&nbsp;https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-market<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/3a4596ac3f1e12d31a6250bc5581e261.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Key pharma companies:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Merck<br \/>2. GlaxoSmithKline<br \/>3. Abbvie<br \/>4. Pfizer<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs involved:<\/strong> <br \/>1. Proscar<br \/>2. Avodart<br \/>3. Jalyn<br \/>4. Hytrin<\/p>\n<p style=\"text-align: justify;\"><strong>Download a free sample report<\/strong> @https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-market<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<br \/>2. Executive Summary of Benign prostatic hyperplasia (BPH)<br \/>3. Competitive Intelligence Analysis for Benign prostatic hyperplasia (BPH)<br \/>4. Benign prostatic hyperplasia (BPH): Market Overview at a Glance<br \/>5. Benign prostatic hyperplasia (BPH): Disease Background and Overview<br \/>6. Patient Journey<br \/>7. Benign prostatic hyperplasia (BPH) Epidemiology and Patient Population<br \/>8. Treatment Algorithm, Current Treatment, and Medical Practices<br \/>9. Unmet Needs<br \/>10. Key Endpoints of Benign prostatic hyperplasia (BPH) Treatment<br \/>11. Marketed Products<br \/>12. Emerging Therapies<br \/>12.1. Key Cross<br \/>13. Benign prostatic hyperplasia (BPH): Seven Major Market Analysis<br \/>14. Attribute analysis<br \/>15. 7MM: Market Outlook<br \/>16. Access and Reimbursement Overview of Benign prostatic hyperplasia (BPH)<br \/>17. KOL Views<br \/>18. Market Drivers<br \/>19. Market Barriers<br \/>20. Appendix<br \/>21. DelveInsight Capabilities<br \/>22. Disclaimer<br \/>23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/benign-prostatic-hyperplasia-bph-epidemiology-forecast\" target=\"_blank\">Benign prostatic hyperplasia (BPH) &#8211; Epidemiology Forecast to 2030<\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/benign-prostatic-hyperplasia-bph-pipeline-insight\" target=\"_blank\">Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020<\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_55879.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=benign-prostatic-hyperplasia-bph-market-insights-epidemiology-and-market-forecast2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=benign-prostatic-hyperplasia-bph-market-insights-epidemiology-and-market-forecast2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&#8217;s &#8220;Benign prostatic hyperplasia (BPH) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Benign prostatic hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign prostatic hyperplasia (BPH) market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/benign-prostatic-hyperplasia-bph-market-insights-epidemiology-and-market-forecast2030_474396.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-474396","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=474396"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474396\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=474396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=474396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=474396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}